New hope for frail AML patients: less toxic drug combo shows promise

NCT ID NCT07236931

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination using selinexor with fewer or no harsh chemo drugs for adults newly diagnosed with acute myeloid leukemia (AML) who are too frail for standard intensive chemo. The goal is to quickly reduce leukemia cells while causing fewer side effects. About 71 participants will be followed to see if this approach improves survival and allows doctors to adjust treatment early based on how the patient responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••